D018796Chemicals & DrugsD12.776.124.790.651.114.580D12.776.377.715.548.114.58010100.99236ImmunoconjugatesFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson0.4211040.016160610research area of0.87810.065139911subject area for24670180Alachkar N, Carter-Monroe N, Reiser JThe New England journal of medicineAbatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2014 03 27; 370(13):1263-4.N Engl J Med2014-03-27T00:00:002014Abatacept in B7-1-positive proteinuric kidney disease.24375054Reiser J, Alachkar NNature reviews. NephrologyProteinuria: abate or applaud abatacept in proteinuric kidney disease? Nat Rev Nephrol. 2014 03; 10(3):128-30.Nat Rev Nephrol2013-12-24T00:00:002013Proteinuria: abate or applaud abatacept in proteinuric kidney disease?24206430Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW, Mundel PThe New England journal of medicineAbatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013 Dec 19; 369(25):2416-23.N Engl J Med2013-11-08T00:00:002013Abatacept in B7-1-positive proteinuric kidney disease.AugustineManadanAugustine M. Manadan349421Manadan, AugustineProfessorTheodorePincusTheodore Pincus349493Pincus, TheodoreProfessorMary JoFidlerMary Jo Fidler349589Fidler, Mary JoAssociate ProfessorJoelBlockJoel Block349607Block, JoelProfessor5Associate Professor4ProfessorRush University, Rush Medical CollegeVineetGuptaVineet Gupta41.87386750000000-87.67102690000000349018Gupta, VineetAssociate Professor34338127Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, Evens AM, Pro BLeukemia & lymphomaA phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV?+?lymphomas. Leuk Lymphoma. 2021 12; 62(14):3493-3500.Leuk Lymphoma2021-08-02T00:00:002021A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV?+?lymphomas.35165101Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JFClinical cancer research : an official journal of the American Association for Cancer ResearchPraluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.Clin Cancer Res2022-05-13T00:00:002022Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.Internal Medicine, Division of Hematology/Oncology/Cell Therapytrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorInternal Medicine, Division of NephrologyInternal Medicine, Division of Rheumatology